- Home
- PLUR vs GRCE Comparison
PLUR vs GRCE Comparison
Compare PLUR & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- GRCE
- Stock Information
- Founded
- PLUR 2001
- GRCE 2002
- Country
- PLUR Israel
- GRCE United States
- Employees
- PLUR N/A
- GRCE N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- GRCE
- Sector
- PLUR Health Care
- GRCE
- Exchange
- PLUR Nasdaq
- GRCE NYSE
- Market Cap
- PLUR 41.9M
- GRCE 41.2M
- IPO Year
- PLUR N/A
- GRCE N/A
- Fundamental
- Price
- PLUR $4.50
- GRCE $2.97
- Analyst Decision
- PLUR
- GRCE Strong Buy
- Analyst Count
- PLUR 0
- GRCE 1
- Target Price
- PLUR N/A
- GRCE $12.00
- AVG Volume (30 Days)
- PLUR 18.1K
- GRCE 27.2K
- Earning Date
- PLUR 05-13-2025
- GRCE 06-03-2025
- Dividend Yield
- PLUR N/A
- GRCE N/A
- EPS Growth
- PLUR N/A
- GRCE N/A
- EPS
- PLUR N/A
- GRCE N/A
- Revenue
- PLUR $1,034,000.00
- GRCE N/A
- Revenue This Year
- PLUR $472.39
- GRCE N/A
- Revenue Next Year
- PLUR $254.29
- GRCE N/A
- P/E Ratio
- PLUR N/A
- GRCE N/A
- Revenue Growth
- PLUR 203.23
- GRCE N/A
- 52 Week Low
- PLUR $3.33
- GRCE $1.75
- 52 Week High
- PLUR $7.13
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- PLUR 44.62
- GRCE N/A
- Support Level
- PLUR $4.60
- GRCE N/A
- Resistance Level
- PLUR $5.30
- GRCE N/A
- Average True Range (ATR)
- PLUR 0.40
- GRCE 0.00
- MACD
- PLUR -0.10
- GRCE 0.00
- Stochastic Oscillator
- PLUR 20.40
- GRCE 0.00
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.